Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

NCT00643045 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

269

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG: Safinamide
DRUG: Safinamide
DRUG: Placebo

Sponsor

Newron Pharmaceuticals SPA